



# Bal Pharma Limited

29.06.2021

The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

BSE Limited  
Mumbai.

Dear Sir,

**Sub : Outcome of the Board Meeting.**

The Board of Directors of the Company has met today and *inter alia* transacted the following business.

1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2021. A copy of the Audited financials (Standalone and Consolidated) along with audit report's are enclosed with this letter for submission to the exchanges.

2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company.

4. Decided to convene the 34<sup>th</sup> Annual General Meeting of the Company on Friday 24<sup>th</sup> September, 2021, by audio visual means.

5.Decided to close the Register of Members and Share Transfer books of the Company from 18<sup>th</sup> September 2021 to 24<sup>th</sup> September 2021 (Both days inclusive).

6.The Board considered and authorised Mr.Shailesh Siroya, Managing Director to undertake restructuring process of the group Companies, subject to various legal and taxation aspects.

The meeting commenced at 4.00 p.m and concluded at 5.30 p.m on 29.06.2021.

Please take this intimation on record.

For Bal Pharma Limited

Shailesh Siroya  
Managing Director



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : [Info@balpharma.com](mailto:Info@balpharma.com) Website : [www.balpharma.com](http://www.balpharma.com)

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820



**Independent Auditor's Report on Audited Standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**Independent Auditor's Report**

To the Board of Directors of Bal Pharma Limited

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone annual financial results of Bal Pharma Limited (herein after referred to as "the Company") for the year ended March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended March 31, 2021.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.





### **Emphasis of Matter**

We refer to Note 4 with regard to recoverability of outstanding receivables from the subsidiary companies.

Our opinion is not modified with regard to above matters.

### **Management's and Board of Directors' Responsibilities for the Standalone Financial Results**

These financial results, which is the responsibility of the Company's Management and approved by Board of Directors, has been compiled from the related audited interim financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.



## Auditor's Responsibilities for the Audit of the Standalone Financial Results (continued)

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





### **Other Matter**

The standalone financial results include the results for the quarter ended 31 March 2021, being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the current financial year which were subjected to limited review by us.

*for* **NSVM & Associates**

Chartered Accountants

Firm Registration Number: 010072S



**G.C.S Mani**

Partner

Membership Number: 036508



Place: Bengaluru

Date: 29 June, 2021

UDIN: 21036508AAAADE9601



**BAL PHARMA LIMITED**  
CIN: L8510KA1987PL1008308  
Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099  
**STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2021**

(₹ in Lakhs except EPS)

Sl No.	Particulars	Standalone				
		Quarter Ended		Year ended		
		31 March 2021 Audited	31 December 2020 Unaudited	31 March 2020 Audited	31 March 2021 Audited	31 March 2020 Audited
I	Income					
	Revenue from operations	7,078.50	6,269.55	3,376.93	34,930.88	17,067.78
II	Other income	117.21	64.05	162.88	269.20	362.86
III	<b>Total Income - (I)+(II)</b>	<b>7,145.71</b>	<b>6,333.60</b>	<b>3,539.81</b>	<b>15,200.08</b>	<b>17,430.64</b>
IV	Expenses					
	a) Cost of materials consumed	4,284.12	3,497.61	928.39	13,516.85	7,268.55
	b) Purchase of Stock-in-trade	264.82	204.87	182.12	997.83	870.39
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-308.57	83.04	436.22	513.31	232.06
	d) Employee benefit expenses	1,020.75	1,047.48	1,054.61	1,968.85	4,878.22
	e) Finance costs	312.18	285.69	300.38	1,195.87	1,255.03
	f) Depreciation and amortization expense	232.61	163.54	303.12	775.66	702.65
	g) Other expenses	1,061.63	888.55	641.89	3,279.16	3,030.85
	<b>Total Expense - (IV)</b>	<b>6,877.54</b>	<b>6,068.78</b>	<b>3,851.83</b>	<b>24,770.47</b>	<b>18,137.76</b>
V	<b>Profit before Exceptional item and Tax (III-IV)</b>	<b>268.17</b>	<b>234.82</b>	<b>(312.02)</b>	<b>929.61</b>	<b>(907.62)</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit/(Loss) before Tax (V-VI)</b>	<b>268.17</b>	<b>234.82</b>	<b>(312.02)</b>	<b>929.61</b>	<b>(907.62)</b>
VIII	Less: Tax Expense	(169.71)	79.88	39.80	69.93	(17.42)
IX	<b>Net Profit for the period</b>	<b>497.88</b>	<b>154.94</b>	<b>(351.82)</b>	<b>999.68</b>	<b>(890.20)</b>
X	Other Comprehensive Income (OCI)					
	- Items that may not be reclassified to Profit or loss	57.48	-	(41.11)	12.18	(41.11)
	- Income tax relating to items that will not be reclassified to profit or loss	(3.62)	-	10.69	(3.63)	10.69
	<b>Total Other Comprehensive Income, net of Income Tax</b>	<b>8.85</b>	<b>-</b>	<b>(30.42)</b>	<b>8.85</b>	<b>(30.42)</b>
XI	<b>Total Comprehensive income for the period (IX+X)</b>	<b>446.73</b>	<b>154.94</b>	<b>(382.25)</b>	<b>918.53</b>	<b>(920.63)</b>
XII	Paid-up Equity Share Capital (Face value ₹ 10 per share)	1,182.24	1,417.24	1,117.24	1,482.24	1,117.24
XIII	Other Equity	-	-	-	6,419.52	5,177.24
XIV	Earnings per share (Face value of ₹ 10 each)					
	Basic - in ₹	3.08	1.09	(2.48)	6.41	(5.28)
	Diluted - in ₹	3.08	1.08	(2.48)	6.41	(5.28)
	See accompanying notes to the audited standalone financial results					

**Notes:**

- The above Audited standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29 June, 2021.
- The standalone financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable.
- The Board has recommended a Dividend of ₹ 1 per equity share of ₹ 10 each, for the financial year 2020-21.
- The Government of India, on 20 September 2019, vide the Taxation laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- The Company has a outstanding recoverability of ₹ 796.49 lakhs and ₹ 118.27 lakhs from its subsidiaries Lifecare Healthcare Private Limited and Balsee Clinic LLP. The said subsidiaries have incurred losses and have a negative networth. However the management is considering restructuring its subsidiaries so as to recover the outstandings.
- The Company has not received any intimation or information with regard to its vendor registration as a Micro, Small and medium enterprises. Accordingly, the entire dues to vendors has been classified as payable to other than MSME.
- The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. However, the Company has not experienced any significant or material difficulties with respect to market demand, collections or liquidity and the management expects no impairment is required for the carrying amount of these assets. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.
- The Company has during the year purchased 919000 shares of Lifecare Healthcare Private Limited thereby increasing its holding to 99.45%.
- The Company has only one reportable segment namely "Pharmaceuticals".
- The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the period presentation.

Place: Bangalore  
Date: 29th June, 2021



By the order of the Board  
Bal Pharma Limited  
Shailesh D. Niraya  
Managing Director



**BAL PHARMA LIMITED**  
**CIN: L85110KA1987PLC008368**

**Standalone Balance Sheet**

(all amounts in Rs. lakhs unless otherwise stated)

	As at 31 March 2021	As at 31 March 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	4,542.41	4,974.45
Capital work-in-progress	-	10.58
Other Intangible Assets	722.74	639.08
Intangible assets under development		
Financial assets		
- Investments	839.60	741.69
- Loans	32.82	24.50
- Other financial assets	248.89	156.10
Non Current tax assets (Net)	14.75	-
Other non-current assets	432.78	513.78
	<u>6,833.99</u>	<u>7,060.18</u>
<b>Current assets</b>		
Inventories	6,012.03	6,754.87
Financial assets		
- Trade receivable	6,944.09	5,165.91
- Loans	2,069.51	1,743.71
- Cash and cash equivalents	89.09	67.64
- Other bank balances	282.70	227.31
- Other financial assets	180.33	182.00
Current tax assets (Net)	0.35	9.78
Other current assets	3,741.87	2,719.92
	<u>19,319.97</u>	<u>16,871.14</u>
	<u>26,153.96</u>	<u>23,931.32</u>
<b>EQUITY &amp; LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,482.24	1,417.24
Other equity	6,449.52	5,177.24
	<u>7,931.76</u>	<u>6,594.48</u>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
- Borrowings	2,393.21	2,314.65
- Other financial liabilities	304.40	267.43
Provisions	396.83	354.64
Deferred tax liabilities (Net)	440.48	404.80
	<u>3,534.92</u>	<u>3,341.52</u>
<b>Current liabilities</b>		
Financial liabilities		
- Borrowings	7,505.05	7,060.63
- Trade payables		
Due to Micro, Small and Medium Enterprises		
Due to Other than Micro, small and Medium Enterprises	4,855.50	3,945.17
- Other financial liabilities	1,327.52	1,431.31
Other current liabilities	902.28	1,508.93
Provisions	64.66	49.28
Current tax liabilities (Net)	32.26	-
	<u>14,687.27</u>	<u>13,995.32</u>
	<u>26,153.96</u>	<u>23,931.32</u>



**BAL PHARMA LIMITED**

CIN: L85110KA1987PLC008368

**Standalone Statement of Cash Flows**

(all amounts in Rs. lakhs unless otherwise stated)

	For the year ended 31 March 2021	For the year ended 31 March 2020
<b>Cash flow from operating activities:</b>		
Profit / (Loss) before tax	979.61	(907.62)
Adjustment for :		
- Interest income	(171.24)	(209.63)
- (Gain)/Loss on sale of Property, Plant and Equipment	(4.06)	(5.25)
- Balances written off as no more payable	(57.81)	(45.47)
- Unrealised Foreign (Gain)/Loss	46.61	3.83
- Finance cost (including effect of amortisation of processing fees)	1,195.82	1,241.57
- Interest on Income Tax	-	4.79
- Rental Expense(IND AS 116)	(90.15)	(80.53)
- Balances written off as no more receivable	77.72	31.95
- Depreciation and amortisation	725.66	702.65
- Expected Credit Losses	21.17	22.38
- Impairment on Investments	-	2.50
<b>Operating cash flow before working capital changes</b>	<b>2,723.32</b>	<b>761.18</b>
Changes in		
- Decrease/(Increase) in Inventories	742.84	196.72
- Decrease/(Increase) in Trade receivables	(1,868.71)	1,239.32
- Decrease/(Increase) in Loans	(8.32)	36.87
- Decrease/(Increase) in Financial Assets (Current and Non current)	(14.58)	(14.12)
- Decrease/(Increase) in Other Assets (Current and Non current)	(1,018.89)	310.33
- Increase/ (Decrease) in Trade payables	958.68	(812.74)
- Increase/ (Decrease) in Other Financial liabilities (Current and Non current)	57.04	525.13
- Increase/ (Decrease) in Other liabilities (Current and Non current)	(606.64)	(142.01)
- Increase/ (Decrease) in Provisions	70.04	87.99
<b>Cash (used in)/ generated from operations</b>	<b>1,034.78</b>	<b>2,188.66</b>
Income taxes (paid)/ refund	(10.93)	(17.21)
<b>Net cash generated (used in) operating activities</b>	<b>1,023.85</b>	<b>2,171.45</b>
<b>Cash flow from investing activities:</b>		
Purchase of Property, Plant & Equipment including intangible assets and capital work-in-progress	(285.24)	(359.92)
Intercompany Deposit to Subsidiary	(189.33)	-
Interest Income from subsidiary	-	-
Investment in Subsidiaries	(97.91)	-
Proceeds from sale of fixed assets	4.06	0.53
Decrease/ (increase) in fixed deposits	(124.54)	9.76
Interest received	27.40	33.96
<b>Net cash generated/ (used in) investing activities</b>	<b>(665.56)</b>	<b>(315.68)</b>
<b>Cash flow from financing activities:</b>		
(Repayment) of long term borrowings	(366.36)	(879.67)
Proceeds from long term borrowings	400.00	-
Proceeds from / (repayment) of short term borrowings	399.27	254.79
Dividend Paid including unpaid dividends of preceding years	-	(141.72)
Payment of Dividend Distribution Tax	(29.13)	-
Money received on issue of Equity shares	325.00	-
Money received against Share Warrants	93.75	-
Interest Paid (Gross)	(1,159.00)	(1,227.04)
<b>Net cash arising/ (used in) from financing activities</b>	<b>(336.48)</b>	<b>(1,993.64)</b>
<b>Net (decrease)/ increase in cash and cash equivalents</b>	<b>21.81</b>	<b>(137.87)</b>
Cash and cash equivalents at the beginning of the year	67.64	219.74
Effect of exchange differences on cash and cash equivalents	(0.36)	(14.23)
<b>Cash and cash equivalents at the end of the year</b>	<b>89.09</b>	<b>67.64</b>
<b>Cash and cash equivalents comprise of:</b>		
Cash on hand	17.34	17.05
Balances with banks		
- in current accounts	69.73	24.67
- in deposits with original maturity of less than 3 months	2.02	26.22
	<b>89.09</b>	<b>67.94</b>

The above statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, "Statement of cash flows".







**Independent Auditor's Report on Audited consolidated Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**Independent Auditor's Report**

To the Board of Directors of Bal Pharma Limited

**Report on the audit of the Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated annual financial results of Bal Pharma Limited (hereinafter referred to as "the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2021, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial results of the subsidiaries, these consolidated financial results:

i. includes the results of the following entities:

Lifezen Health care Private limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary
Golden drugs Private limited	Subsidiary

ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and



- iii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2021.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 (the Act) and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of the audit reports of the other auditors referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

#### **Management's and Board of Directors' Responsibilities for the Consolidated Financial Results**

These consolidated financial results, which is the responsibility of the Holding Company's Management and approved by Board of Directors, has been compiled from the related audited consolidated financial statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.





## **Management's and Board of Directors' Responsibilities for the Consolidated Financial Results** (continued)

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of the Group.

## **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.



## Auditor's Responsibilities for the Audit of the Consolidated Financial Results (continued)

- Conclude on the appropriateness of the Managements and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

### Other Matter

The consolidated Financial Results include the audited Financial Results of four subsidiaries, whose Financial Statements/Financial Results/ financial information reflect total assets (before consolidation





## Other Matter (continued)

adjustments ) of ₹ 1,923.90 lakhs as at 31 March 2021, total revenue (before consolidation adjustments) of ₹ 271.84 lakhs for year ended, total net (loss) after tax (before consolidation adjustments) of ₹ (445.49) lakhs for year ended 31 March, 2021 and net cash flow outflows (before consolidation adjustments) of ₹ 4.97 lakhs for the year ended on that date as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on Financial Results and financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

We further state that the Holding Company is a partner in a joint venture floated outside India and during the year the management has agreed to terminate the same. We were informed by the management that no operations have been commenced and hence no books of accounts have been maintained. The Joint venture has therefore not been considered for the purpose of consolidation. (Refer note 3 to Consolidated Financial Results)

Our opinion on the consolidated Financial Results is not modified in respect of the above matter.

The Statement includes the consolidated financial results for the quarter ended 31 March 2021, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

for NSVM & Associates

Chartered Accountants

Firm Registration Number: 010072S

  
G.C.S Mami

Partner


Membership Number: 036508



Place: Bengaluru

Date: 29 June, 2021

UDIN: 21036508AAAADG7030



it is. Labels count! EPS

Sl No.	Particulars	Consolidated				
		Quarter ended			Year ended	
		31 March 2021 Audited	31 December 2020 Unaudited	31 March 2020 Audited	31 March 2021 Audited	31 March 2020 Audited
I	<b>Income</b>					
i	Revenue from operations	1,044.05	6,532.80	3,377.75	25,047.56	12,169.43
ii	Other income	72.78	19.14	117.37	113.84	181.42
III	<b>Total Income - (I+II)</b>	<b>7,454.78</b>	<b>6,321.81</b>	<b>3,495.11</b>	<b>25,161.40</b>	<b>12,350.85</b>
IV	<b>Expenses</b>					
	Cost of materials consumed	4,284.12	3,197.59	896.82	13,546.88	7,208.63
	Purchase of Stock-in-trade	295.20	26.41	158.99	1,089.01	851.28
	(Increase)/decrease in inventory of finished goods and work-in-progress	(376.17)	(2.92)	454.39	204.88	338.31
	Employee benefits expenses	1,697.31	1,006.84	1,121.40	4,187.61	5,051.30
	Finance costs	311.65	789.10	932.84	1,197.42	1,215.75
	Depreciation and amortisation expense	343.65	209.20	558.81	952.42	707.70
	Other expenses	1,629.51	904.81	975.39	3,324.53	3,129.83
	<b>Total Expense - (IV)</b>	<b>7,165.55</b>	<b>6,380.05</b>	<b>2,955.09</b>	<b>24,126.43</b>	<b>18,617.88</b>
V	<b>Profit before Exceptional Item and Tax (III-IV)</b>	<b>52.83</b>	<b>119.88</b>	<b>(459.41)</b>	<b>410.27</b>	<b>(1,352.98)</b>
VI	Exceptional Item	-	-	-	-	-
VII	<b>Profit/loss before Tax (V+VI)</b>	<b>52.83</b>	<b>119.88</b>	<b>(459.41)</b>	<b>410.27</b>	<b>(1,352.98)</b>
VIII	<b>Tax Expense</b>	<b>(30.26)</b>	<b>79.97</b>	<b>(6.31)</b>	<b>(60.50)</b>	<b>(65.76)</b>
IX	<b>Net Profit for the period</b>	<b>22.89</b>	<b>40.10</b>	<b>(477.67)</b>	<b>349.77</b>	<b>(1,418.74)</b>
	<b>Profit/(Loss) attributable to:</b>					
	- Equity holders of the parent company	22.89	40.10	(477.67)	349.77	(1,418.74)
	- Non controlling interest	-	-	-	-	-
X	<b>Other Comprehensive Income(OCI)</b>					
	- Items that may not be reclassified to Profit or loss	18.84	-	(39.71)	13.81	(39.71)
	- Income tax relating to items that will not be reclassified to Profit or loss	(3.63)	-	10.69	(3.63)	10.69
	<b>Total Other Comprehensive Income, net of Income Tax</b>	<b>15.21</b>	<b>-</b>	<b>(29.02)</b>	<b>10.18</b>	<b>(29.02)</b>
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>38.10</b>	<b>40.10</b>	<b>(506.69)</b>	<b>359.95</b>	<b>(1,447.76)</b>
	<b>Total Comprehensive Income/(Loss) attributable to:</b>					
	- Equity holders of the parent company	38.10	40.10	(506.69)	359.95	(1,447.76)
	- Non controlling interest	-	-	-	-	-
XII	<b>Paid up Equity Share Capital (Face value ₹ 10 per share)</b>	<b>1,187.24</b>	<b>1,187.24</b>	<b>1,187.21</b>	<b>1,187.70</b>	<b>1,187.24</b>
XIII	<b>Other Equity</b>				<b>1,805.91</b>	<b>3,825.38</b>
XIV	<b>Earnings per share (Face value of ₹ 10 each)</b>					
	Basic - in ₹	2.52	0.22	(3.22)	3.31	(8.62)
	Diluted - in ₹	2.52	0.22	(3.21)	3.31	(8.62)

- 1 The above Audited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29 June, 2021.
- 2 The consolidated financial results has been prepared in accordance with the Corporate Income Accounting Standards (Rules, 2015) (BISAS), prescribed under section 133 of the Companies Act, 2013, save with minor modifications thereto and other recognized accounting policies not being contrary applicable. The audited consolidated financial results relate to Baflyforms Limited, its subsidiaries (together constitute the group) Joint Venture and Associates and are prepared by applying BRS AS 110 - "Intermediate Financial Statements", and BRS AS 28 - "Disclosure in Associates & Joint Ventures".
- 3 The Baflyforms Group had entered into a Joint Venture agreement with Akhil Finance Pvt. Limited, Andhra Pradesh and during the year, the management has decided to terminate the agreement. As no consummated operations commenced, the same is not included in consolidated results.
- 4 The Group has not received any information or information with regard to the business registration as a Micro, Small and medium enterprise. Accordingly, the entire duty to comply has been observed as payable to other than MSME.
- 5 The Government of India, on 20 September 2019, vide the Taxation law (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income Tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates on per the provisions and conditions defined in the said section. The Company has evaluated the above Ordinance and based on representation currently the management proposed to continue with the old tax rate.
- 6 The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Group continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. Based on internal and external sources of information, current economic assessment and future economic indicators, the Group has assessed the financial impact of the COVID-19 situation on its operations particularly on the varying amounts of cash flow, inventory, property, plant and equipment and intangible assets. However, the Group has not experienced any significant or material difficulties with respect to market demand, collection of liquidity and the management expects no impairment is required for the carrying amount of these assets. However, the impact of the pandemic could be different from those estimated today involving the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.
- 7 The Company has purchased 99,000 shares of Lifecare Healthcare Private Limited during the year and thereby increasing the holding to 99.190. The same has resulted in changes in the proportion of equity held by non-controlling interests. The Company has agreed the company amounts of the controlling and noncontrolling interests to reflect the share in their relative interests in the subsidiary in accordance with the AS 110. The entity has recognized duly in equity any difference between the amount by which the noncontrolling interests are adjusted on the formation of the consolidation paid.
- 8 The Group has only one reportable segment namely, Pharmaceuticals.
- 9 The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figure between the audited figures in respect of the 9th financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject limited review by the Statutory Auditor of the Company.
- 10 Previous period figures have been reported/omitted wherever considered necessary for continuity in the period presentation.

By Order of the Board:  
 Hoechst Pharmas Limited  
  
 Shashik D. Singh  
 Managing Director





**BAL PHARMA LIMITED**  
**CIN: L85110KA1987PLC008368**

**Consolidated Balance Sheet**

(all amounts in Rs. lakhs unless otherwise stated)

	As at 31 March 2021	As at 31 March 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	5,750.87	6,044.85
Capital work-in-progress	-	332.09
Goodwill	382.86	382.86
Other Intangible Assets	724.83	642.83
Financial assets		
- Investments	-	-
- Loans	38.34	29.18
- Other financial assets	248.89	156.10
Non Current tax assets (Net)	14.75	-
Other non-current assets	432.78	513.93
	<u>7,593.32</u>	<u>8,101.84</u>
<b>Current assets</b>		
Inventories	6,038.53	6,771.13
Financial assets	-	-
- Trade receivable	6,719.70	4,960.24
- Loans	206.38	220.79
- Cash and cash equivalents	102.34	85.87
- Other bank balances	282.70	227.31
- Other financial assets	180.32	182.00
Current tax assets (Net)	1.60	10.79
Other current assets	2,883.15	3,278.74
	<u>16,414.72</u>	<u>15,736.87</u>
	<u>24,008.04</u>	<u>23,838.71</u>
<b>EQUITY &amp; LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,482.24	1,417.24
Other equity	3,875.91	3,825.38
Non Controlling Interest	(22.78)	(709.53)
	<u>5,335.37</u>	<u>4,533.08</u>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
- Borrowings	2,393.20	2,314.66
- Other financial liabilities	356.43	321.43
Provisions	406.54	361.98
Deferred tax liabilities (Net)	263.21	358.39
	<u>3,419.39</u>	<u>3,356.46</u>
<b>Current liabilities</b>		
Financial liabilities		
- Borrowings	8,081.89	8,962.63
- Trade payables		
Due to Micro, Small and Medium Enterprises		
Due to Other than Micro, small and Medium Enterprises	4,716.65	3,867.41
- Other financial liabilities	1,442.55	1,540.22
Other current liabilities	914.32	1,529.04
Provisions	65.61	49.87
Current tax liabilities (Net)	32.26	-
	<u>15,253.28</u>	<u>15,949.17</u>
	<u>24,008.04</u>	<u>23,838.71</u>



**BAL PHARMA LIMITED**

CIN: L85110KA1987PLC008368

**Consolidated Statement of Cash Flows**

(all amounts in Rs. lakhs unless otherwise stated)

	For the year ended 31 March 2021	For the year ended 31 March 2020
<b>Cash flow from operating activities:</b>		
Profit / (Loss) before tax	410.27	(1,352.93)
Adjustment for :		
- Interest income	(27.40)	(38.70)
- (Gain)/Loss on sale of Property, Plant and Equipment	(2.10)	(5.25)
- Balances written off as no more payable	(58.27)	(46.62)
- Unrealised Foreign (Gain)/Loss	43.80	3.83
- Finance cost (including effect of amortisation of processing fees)	1,197.42	1,245.25
- Interest on Income Tax	-	4.79
- Rental Expense(IND AS 116)	(90.15)	(86.13)
- Balances written off as no more receivable	77.72	31.95
- Depreciation and amortisation	952.12	22.38
- Expected Credit Losses	21.17	767.76
- Impairment on Investments	-	1.50
<b>Operating cash flow before working capital changes</b>	<b>2,524.58</b>	<b>547.85</b>
Changes in		
- Decrease/(Increase) in Inventories	732.61	203.98
- Decrease/(Increase) in Trade receivables	(1,850.00)	1,346.75
- Decrease/(Increase) in Loans (Current and Non current)	(9.16)	38.46
- Decrease/(Increase) in Financial Assets (Current and Non current)	14.42	(2.59)
- Decrease/(Increase) in Other Assets (Current and Non current)	398.80	458.84
- Increase/(Decrease) in Trade payables	898.05	(875.22)
- Increase/(Decrease) in Other Financial liabilities (Current and Non current)	75.95	455.88
- Increase/(Decrease) in Other liabilities (Current and Non current)	(614.71)	116.13
- Increase/(Decrease) in Other Bank Balances	(55.39)	(38.56)
- Increase/(Decrease) in Provisions	74.14	90.04
<b>Cash (used in)/ generated from operations</b>	<b>2,189.29</b>	<b>2,341.55</b>
Income taxes (paid)/ refund	(11.17)	(17.21)
<b>Net cash generated (used in) operating activities</b>	<b>2,178.12</b>	<b>2,324.34</b>
<b>Cash flow from investing activities:</b>		
Purchase of Property, Plant & Equipment including intangible assets and capital work-in-progress	(341.34)	(506.32)
Unrealised Foreign (Gain) / Loss	2.81	-
Acquisition of Subsidiaries	(97.91)	-
Proceeds from sale of fixed assets	2.10	1.84
Decrease/ (increase) in fixed deposits	(91.11)	-
Interest received	27.40	33.96
<b>Net cash generated/ (used in) investing activities</b>	<b>(498.05)</b>	<b>(470.52)</b>
<b>Cash flow from financing activities:</b>		
(Repayment) of long term borrowings	(366.37)	(879.67)
Proceeds from long term borrowings	400.00	-
Proceeds from / (repayment) of short term borrowings	(925.88)	254.79
Dividend Paid including unpaid dividends of preceding years	-	(141.72)
Payment of Dividend Distribution Tax	(29.13)	-
Money received on issue of Equity shares	325.00	-
Money received against Share Warrants	93.75	-
Interest Paid (Gross)	(1,160.60)	(1,230.72)
<b>Net cash arising/ (used in) from financing activities</b>	<b>(1,663.24)</b>	<b>(1,997.32)</b>
<b>Net (decrease)/ increase in cash and cash equivalents</b>	<b>16.83</b>	<b>(143.50)</b>
Cash and cash equivalents at the beginning of the year	85.87	243.60
Effect of exchange differences on cash and cash equivalents	(0.36)	(14.23)
<b>Cash and cash equivalents at the end of the year</b>	<b>102.34</b>	<b>85.87</b>
<b>Cash and cash equivalents comprise of:</b>		
Cash on hand	19.64	27.66
Balances with banks		
- in current accounts	80.69	31.95
- in deposits with original maturity of less than 3 months	2.01	26.72
	<b>102.34</b>	<b>85.87</b>

The above statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, "Statement of cash flows".

